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FEV1 = forced expiratory volume in one second; GC = glucocorticoid; GRE = glucocorticoid response element; PBMC = peripheral blood
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Introduction
Glucocorticoids (GCs) are involved in the regulation of
numerous physiological processes and, as drugs, repre-
sent the cornerstone of anti-inflammatory treatment in
asthma. Their effects are mediated by the glucocorticoid
receptor a (GRa). Upon ligand-binding, GRa inhibits or
stimulates gene transcription. Different mechanisms for
negative transcriptional regulation by GRa have been
described, but the most common is transrepression,
which involves inhibitory protein–protein interactions
between GRa and other transcription factors like AP-1
and NF-kB [1]. These transcription factors stimulate the
expression of many genes encoding inflammatory media-
tors. Stimulation of gene transcription, or transactivation,
occurs after binding of the hormone-activated GRa to GC
response elements (GREs) on DNA. These are found in
another set of genes like those involved in the control of
neoglucogenesis, arterial pressure and intraocular tension
(genes and references are listed in [2]). GCs also transac-
tivate the b2-adrenergic receptor gene and may, conse-
quently, facilitate bronchodilatory action of b2-agonists
[3,4]. It should be noted that GCs induce expression of
IkBa, an inhibitor of NF-kB, and may therefore counteract
inflammation through transactivation. However, recent
data suggest that induction of IkBa by GCs is neither
required nor sufficient for the downmodulation of NF-kB
activity [5–7]. Possibly, other genes encoding anti-inflam-
matory proteins might be upregulated by GCs, but these
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Glucocorticoids (GCs) are routinely used as anti-inflammatory drugs in the treatment of asthma. They
act through binding to glucocorticoid receptor a (GRa), which represses numerous genes encoding
pro-inflammatory mediators. A hormone binding deficient GR isoform named GRb has been isolated in
humans. When overexpressed by transfection, GRb may function as a dominant negative modulator of
GRa. However, to act as such, GRb has to be more abundant than GRa, and conflicting data have
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relative amounts of GRa and GRb in these cells were not determined. In GC-dependent asthmatics,
PBMCs expressed GRa predominantly. No cells containing higher levels of GRb than GRa have yet
been reported in asthmatics. Even if the existence of such cells is demonstrated, the role of GRb in
asthma will remain a matter of controversy because functional studies have given discrepant data.
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remain to be identified. Thus, whereas transrepression of
AP-1 and NF-kB activities is clearly implicated in the anti-
inflammatory effect of GCs [8], transactivation probably
accounts for certain beneficial (eg bronchodilatation) or
adverse effects (diabetes, arterial hypertension,
hydrosodic retention, hypokalemia, glaucoma) of these
hormones when used as drugs.
In addition to the 94 kDa GRa, a receptor isoform of 90
kDa termed GRb is generated by alternative splicing in
humans [9]. GRa and GRb are distinguished by differ-
ences in their molecular weight and carboxy-terminal
sequences [10]. Due to its different carboxy terminus,
GRb is unable to bind the hormone and to transactivate a
GRE-dependent promoter [9,11].
Relative amounts of GRa a and GRb b
It was reported that GRb functions as a dominant negative
inhibitor of GRa-mediated transactivation [12,13]. However,
to act as such, GRb has to be more abundant than GRa,
and conflicting data have been obtained concerning the
relative levels of the two isoforms in cell lines and freshly
isolated human cells.
Using antibodies that recognised both forms of the recep-
tor equally well on western blots, GRa was found to be the
predominant isoform in HeLa cells, lymphocytes [10,14],
and A549 cells (Mathieu, unpublished data). In agreement
with these results, northern blot analyses and quantitative
RT-PCR experiments have demonstrated that GRb mRNA
was 300–600 fold less represented than GRa mRNA in
various human tissues, a T cell line, HeLa cells, and in
PBMCs of a patient with GC-resistant ulcerative colitis
[13,15]. In opposition to these different reports, others
have shown the amount of GRb to be equal or higher than
that of GRa in HeLa cells, various human tissues, and in
transformed lymphocytes from a patient with systemic GC
resistance [16,17]. In these latter studies, the investigators
used two different antisera, one directed against GRa, the
other against GRb, together with standards created by
coupling the immunogenic peptides to albumin. As men-
tioned by Hecht and collaborators [14], it is unclear to
what extent coupling efficiency for the different peptides is
controlled in this experiment and whether a quantitative
comparison between the two isoforms in this fashion is
really valid. The use of a single antibody that recognises a
common epitope in both forms of the receptor seems more
appropriate for quantitative comparison of the isoforms, as
no differences in affinity to this epitope between isoforms
will be expected in western blotting.
Expression of GRb was investigated both in GC-resistant
and in GC-dependent asthma. GC-resistant asthmatics
are defined as patients who have a baseline prebronchodi-
lation forced expiratory volume in 1 s (FEV1) of less than
70–80% predicted which improves by less than 15% fol-
lowing 1–2 weeks of 40 mg prednisolone daily. It should
be noted that this definition does not consider the other
clinical benefits of GCs and, in most studies, GC-resistant
patients often use inhaled and/or systemic GCs. In GC-
resistant asthma, immunohistochemical analyses have
shown that GRb was expressed by an increased number
of PBMCs, airway T cells, and cells found in skin biopsies
of tuberculin responses [18–20]. The ratio of positive cells
for GRa over positive cells for GRb was reduced in GC-
resistant patients compared to GC-sensitive patients [20].
Because these investigators used two different antibodies
that may not recognise GRa and GRb with the same effi-
ciency, it was not possible to determine by this approach
which isoform was predominantly expressed. It should be
noted that resistance to GCs may result from the reduced
expression of GRa, or its lower affinity towards GCs as
observed in certain patients [20,21].
GC-dependent asthmatics have a severe form of the
disease and require long-term treatment with oral, as well
as inhaled, GCs. Systemic GCs are not entirely satisfac-
tory because they produce deleterious side effects. More-
over, despite this treatment, some inflammation may
persist in these patients ([22] and references therein).
Using comparative RT-PCR and antibodies that recognise
both forms of the receptor equally well on western blots, a
predominance of GRa over GRb was found in PBMCs
isolated from normal subjects and asthmatic patients,
including GC-dependent asthmatics [22]. Thus, there is
no convincing evidence as yet for a role of GRb in GC-
dependent asthma.
Unless cells containing higher amounts of GRb than GRa
are isolated from patients with GC-dependent or GC-
resistant asthma, it will be difficult to assign a role to GRb
in these forms of the disease.
Functional analyses of GRb b
The ability of overexpressed GRb to alter transcription
from GC-inducible, AP-1-inducible or NF-kB-inducible
promoters has been examined using transient transfection
and reporter gene assays. The initial observation of a dom-
inant negative effect of GRb on GRa-mediated transacti-
vation in COS-7 [12] and HeLa cells [13] was not
reproduced in Jurkat T cells [23], COS-7 cells [14, 24]
and COS-1 cells [25]. Our results suggest that the domi-
nant negative effect of GRb on transactivation is cell type
specific. Indeed, GRb inhibited GC-induced gene expres-
sion in COS-1 cells and to a lesser extent in A549 cells,
but not in HeLa cells (Mathieu, unpublished data). The
capacity of GRb to prevent hormone-activated GRa from
repressing NF-kB activity is also a subject of controversy.
In one study, GRb had this capacity, suggesting that it
may reduce the anti-inflammatory effects of GCs [26],
whereas in another study, it did not have such a capacity
[24]. Data obtained in our laboratory indicate that GRbdoes not behave as a dominant negative receptor for tran-
srepression of either AP-1 or NF-kB activities. On the con-
trary, GRb significantly repressed these activities
(Mathieu, unpublished data). This result suggests that
overexpression of GRb could form part of a cellular
response destined to counteract inflammation. In line with
this, GC-resistant asthmatics expressed higher amounts
of GRb and developed a weaker reaction to tuberculin as
compared to GC-sensitive asthmatics [20]. GRa also had
a hormone-independent inhibitory effect on AP-1 and NF-
kB activities ([27] and Mathieu, unpublished data), indicat-
ing that the contribution of GRb would be significant only
if found at similar or higher levels within cells than GRa .
Overall, the functional data are conflicting and further
studies will be necessary to clarify this controversy. The
discrepant results may be explained by differences in
experimental procedures. For example, the promoter used
to overexpress GRb, the relative amounts of reporter gene
construct, and GRa or GRb expression vectors were not
the same in every study. Moreover, in many studies
[13,14,23,25,26], the reporter gene assay did not include
a constitutive reporter gene to correct values for variations
in transfection efficiency. This control is of crucial impor-
tance because efficiency of transient transfection may
vary. Without such a control, a variation in transfection effi-
ciency may be misinterpreted as a regulation of the GC-
inducible, AP-1-inducible or NF-kB-inducible promoters.
Conclusion
The involvement of GRb in physiological or pathophysiologi-
cal processes will seem unlikely until this isoform is found
using a recognised quantitative method at higher levels than
GRa in the same cells. Even if the existence of such cells is
demonstrated in future studies, there will be no clear indica-
tion as to the role of GRb. . According to one report, GRb
would be expected to decrease sensitivity to the anti-inflam-
matory action of glucocorticoids [26]. In contrast, other
studies have predicted that it would have no effect at all
[23,24], or that it would have an anti-inflammatory effect
(Mathieu, unpublished data). Development of quantitative
immunoassays like ELISA or RIA to determine the relative
amounts of GRa and GRb in cells from asthmatic patients,
the establishment of cell lines containing an inducible GRb
gene and the generation of transgenic animals overexpress-
ing GRb will eventually help to determine if there is role for
GRb in asthma and other inflammatory diseases.
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